Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Asia 100 ebook

Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.


Spotlight On Earnings


Focus On Asia


Data Analysis


R&D


AstraZeneca ‘Playing To Win’ With Cardiometabolic Combinations

AstraZeneca ‘Playing To Win’ With Cardiometabolic Combinations

 

The UK-based company is playing catch up in obesity, but believes it has a unique offering in a three-in-one therapy now moving into Phase II.

Lazertinib’s US Approval A Catalyst For Oscotec’s Growth

Lazertinib’s US Approval A Catalyst For Oscotec’s Growth

 
• By 

Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.

Viking Excites With Latest Oral VK2735 Weight Loss Data

Viking Excites With Latest Oral VK2735 Weight Loss Data

 
• By 

Viking’s dual GLP-1/GIP agonist VK2735 continues to make headlines for strong efficacy and tolerability with oral and injectable formulations. CinFina reports progress with two new MOAs.

Roche Takes Its Time Before Joining Tricky Alzheimer’s Treatment Market

Roche Takes Its Time Before Joining Tricky Alzheimer’s Treatment Market

 

While Eisai/Biogen and Eli Lilly are focused on knocking down barriers to uptake for their anti-amyloid drugs, Roche hopes it can beat them both on safety and efficacy with its brain shuttle technology.

Business


Vertex Readies For Major Readouts, With Data Due Soon In Big Pain Market

Vertex Readies For Major Readouts, With Data Due Soon In Big Pain Market

 
• By 

Q3 revenue beat consensus and Vertex raised its guidance, but R&D progress was the main highlight across the cystic fibrosis, kidney disease, type 1 diabetes and, particularly, pain pipeline.

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

 
• By 

Public Company Edition: Syndax received all $350m from its royalty financing up front, while KalVista got $100m initially out of up to $179m. Also, Vera, EyePoint and Eledon grossed $300m, $161m and $85m in follow-on offerings, while Neurogene raised $200m in a private placement.

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death

 

The otherwise encouraging data were marred by one patient death, but the company attributed it to the busulfan conditioning regimen and not BEAM-101.

Verona’s Ohtuvayre Off To Flying Start

Verona’s Ohtuvayre Off To Flying Start

 

Sales of its novel COPD therapy in its first quarter on the market were more than double consensus estimates, and Verona sees more to come.

Scrip Originals


Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals

 
• By 

Public Company Edition: Syndax received all $350m from its royalty financing up front, while KalVista got $100m initially out of up to $179m. Also, Vera, EyePoint and Eledon grossed $300m, $161m and $85m in follow-on offerings, while Neurogene raised $200m in a private placement.

Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

Stock Watch: Sanofi’s Seasonal Surge And Novartis’s Material Write-Down

 
• By 

Investors’ different responses to third-quarter sales growth at Sanofi and Novartis left future seasonal sales trends and past business development activity under scrutiny.

Pipeline Watch: Five Approvals And 15 Phase III Readouts

Pipeline Watch: Five Approvals And 15 Phase III Readouts

 
• By 

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Biogen Gets New Chief Medical Officer From BMS

Executives On The Move: Biogen Gets New Chief Medical Officer From BMS

 
• By 

Recent moves in the industry include changes at the top at Fennec Pharmaceuticals, plus Opthea Acquires Chief Financial Officer From Amarin, and Disc Medicine gets a new chief technical officer.